The effects of secondary prevention after coronary revascularization in Taiwan.
Wen-Han FengChun-Yuan ChuPo-Chao HsuWen-Hsien LeeHo-Ming SuTsung-Hsien LinHsueh-Wei YenWen-Chol VoonWen-Ter LaiSheng-Hsiung SheuPublished in: PloS one (2019)
There is still much room to improve class I medication use in secondary prevention for patients after revascularization in Taiwan. Statin could be an effective treatment to improve the outcomes.
Keyphrases
- end stage renal disease
- coronary artery disease
- ejection fraction
- newly diagnosed
- coronary artery bypass grafting
- chronic kidney disease
- cardiovascular disease
- coronary artery
- prognostic factors
- type diabetes
- peritoneal dialysis
- heart failure
- metabolic syndrome
- skeletal muscle
- atrial fibrillation
- left ventricular
- aortic stenosis
- combination therapy
- smoking cessation
- replacement therapy
- insulin resistance
- glycemic control
- transcatheter aortic valve replacement